ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Does Direct-to-Consumer Personal Genetic Testing Improve Gynecological Cancer Screening Uptake among Never-Screened Attendees? A Randomized Controlled Study.International journal of environmental research and public health · 2021Trial
- Outcomes from a Novel Approach to Studying Consumer Genetic Testing for Germline Cancer and Cardiovascular Risk.American journal of medical genetics. Part A · 2025Article
- Health care utilization and behavior changes after workplace genetic testing at a large US health care system.Genetics in medicine : official journal of the American College of Medical Genetics · 2024Article
- Genetics healthcare providers' experiences counseling patients with results from consumer genomic testing.Molecular genetics & genomic medicine · 2024Article
- Future implications of polygenic risk scores for life insurance underwriting.NPJ genomic medicine · 2024Review
- Test-takers' perspectives on consumer genetic testing for hereditary cancer risk.Frontiers in genetics · 2024Article
- Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Natural Language Processing Approaches for Retrieval of Clinically Relevant Genomic Information in Cancer.Studies in health technology and informatics · 2022Article
- Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California.Cancer medicine · 2021Article
- Physician-guided, hybrid genetic testing exerts promising effects on health-related behavior without compromising quality of life.Scientific reports · 2021Article
- Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities.Current genetic medicine reports · 2019Review
- Patients' Medical and Psychosocial Experiences After Detection of aJCO precision oncology · 2019Article
- Ethical Implications of Direct-to-Consumer Hereditary Cancer Tests.JAMA oncology · 2018Article
- Nutritional Genomics and Direct-to-Consumer Genetic Testing: An Overview.Advances in nutrition (Bethesda, Md.) · 2018Review
- Effect of co-payment on behavioral response to consumer genomic testing.Translational behavioral medicine · 2018Article
- Genetic testing for exercise prescription and injury prevention: AIS-Athlome consortium-FIMS joint statement.BMC genomics · 2017Article
- Integrating surgery and genetic testing for the modern surgeon.Annals of translational medicine · 2017Review
- Review
- Open sharing of genomic data: Who does it and why?PloS one · 2017Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Purpose Significant concerns exist regarding the potential for unwarranted behavior changes and the overuse of health care resources in response to direct-to-consumer personal genomic testing (PGT). However, little is known about customers' behaviors after PGT. Methods Longitudinal surveys were given to new customers of 23andMe (Mountain View, CA) and Pathway Genomics (San Diego, CA). Survey data were linked to individual-level PGT results through a secure data transfer process. Results Of the 1,042 customers who completed baseline and 6-month surveys (response rate, 71.2%), 762 had complete cancer-related data and were analyzed. Most customers reported that learning about their genetic risk of cancers was a motivation for testing (colorectal, 88%; prostate, 95%; breast, 94%). No customers tested positive for pathogenic mutations in highly penetrant cancer susceptibility genes. A minority of individuals received elevated single nucleotide polymorphism-based PGT cancer risk estimates (colorectal, 24%; prostate, 24%; breast, 12%). At 6 months, customers who received elevated PGT cancer risk estimates were not significantly more likely to change their diet, exercise, or advanced planning behaviors or engage in cancer screening, compared with individuals at average or reduced risk. Men who received elevated PGT prostate cancer risk estimates changed their vitamin and supplement use more than those at average or reduced risk (22% v 7.6%, respectively; adjusted odds ratio, 3.41; 95% CI, 1.44 to 8.18). Predictors of 6-month behavior include baseline behavior (exercise, vitamin or supplement use, and screening), worse health status (diet and vitamin or supplement use), and older age (advanced planning, screening). Conclusion Most adults receiving elevated direct-to-consumer PGT single nucleotide polymorphism-based cancer risk estimates did not significantly change their diet, exercise, advanced care planning, or cancer screening behaviors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.